Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
IPO Year:
Exchange: NASDAQ
Website: tenaxthera.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $16.00 | Outperform | Leerink Partners |
| 10/14/2024 | $16.00 | Buy | Guggenheim |
| 9/30/2024 | Outperform | William Blair |
10-Q - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
DEF 14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
EFFECT - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
424B3 - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
S-8 - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
S-3 - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
D - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
10-Q - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
Leerink Partners initiated coverage of Tenax Therapeutics with a rating of Outperform and set a new price target of $16.00
Guggenheim initiated coverage of Tenax Therapeutics with a rating of Buy and set a new price target of $16.00
William Blair initiated coverage of Tenax Therapeutics with a rating of Outperform
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. "Having completed the merger with PHPrecisionMed Inc., we now have product development programs in group one and group two pulmonary hypertension patients," stated Anthony DiTonno, Chief Executive Officer of Tenax, "which represent more than 70% of the overall market. "We have begun the open label transition study using the oral formulation of Levosimendan, which was recently acq
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition expands Tenax’s pulmonary hypertension pipeline with the addition of imatinib, a Phase 3 ready candidate. Imatinib is a tyrosine kinase i
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative Sites Now Initiated Cash Runway Through End of 2027 CHAPEL HILL, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced financial results for the third quarter of 2024 and provided a corporate update. "The third quarter showcased strong execution across our compa
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax's CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast. Format: Fireside Chat Presenter: Chris Giordano, President & Chief Executive OfficerDate and ti
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative Sites Initiated In April, Hosted the KOL Event, "LEVEL Setting," Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFpEF and Potential of Levosimendan to Address Disease CHAPEL HILL, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. ("Tenax") (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced
• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • Proceeds also will fund the initiation of a second Phase 3 study planned for 2025, shortening timeline to NDA submission; the protocol for this study will be submitted to FDA for comment CHAPEL HILL, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. ("Tenax") (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases wi
CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $100 million to the Company, before deducting placement agent fees and other private placement expenses. The private placement was led by new investor BVF Partners LP, with par
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent Recently Hosted KOL Event, "LEVEL Setting," Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFpEF and Potential of Levosimendan to Address Disease Raised Approximately $8 Million of Net Proceeds in Registered Public Offering in February 2024 CHAPEL HILL, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040Expressly provides IP protection for levosimendan at all therapeutic doses for use in PH-HFpEF Expressly provides IP protection for levosimendan in combination with various cardiovascular drugs for use in PH-HFpEF Represents the third patent granted to Tenax since March of 2023 protecting the use of levosimendan in the treatment of PH-HFpEF CHAPEL HILL, N.C., April 30, 2024 (GLOBE NEWSWIRE) -- Tena
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease Experts will explain pathophysiology of PH-HFpEF, and mechanistic rationale for levosimendan Update on the ongoing Phase 3 LEVEL Study evaluating TNX-103 (oral levosimendan) for the treatment of PH-HFpEF Tenax to Host Webcast on Thursday, April 18, 2024, at 10:00 am ET CHAPEL HILL, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmac
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S. Intellectual Property Covering the Use of Levosimendan for the Treatment of PH-HFpEF and for Use in Combination with Other Cardiovascular Therapies The Company Secured Global Commercial Rights to Levosimendan for the Treatment of PH-HFpEFThe Company will host a KOL Event, "LEVEL Setting: The Scientific Rationale for Levosimendan as the First Treatment for PH-HFpEF and the Ongoing Phase 3 LEVEL Study," on Thursday, April 18th at 10:00 am ET Link to Register CHAPEL HILL, N.C., March
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company's PH-HFpEF Scientific Advisory Board (SAB). "We are thrilled to welcome Dr. Butler to our Scientific Advisory Board," said Stuart Rich, M.D., Chief Medical Officer of Tenax Therapeutics. "Javed is regarded as one of the most eminent clinical trialists in cardiovascular medicine, and he joins three highly distinguished cardiovascular lead
MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that Tenax Therapeutics appointed Robyn Hunter to its Board of Directors, effective January 28, 2022. Ms. Hunter is an independent director and will chair the Board's audit and compliance committee. "We are very pleased to welcome Robyn to our Board of Directors," said Christopher T. Giordano, President and Chief Executive Officer of Tenax Therapeutics. "Robyn brings a wealth of financial and operational
– Anthony DiTonno Retires from Tenax; Christopher Giordano Appointed as CEO – Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company that address cardiovascular and pulmonary diseases with high unmet medical need, today announced a CEO transition in connection with the retirement of its current CEO: Effective July 13, 2021, Mr. Anthony A. DiTonno will retire as Chief Executive Officer and Director of the Company, following a successful decade of service with the Company. The Board has appointed Mr. Christopher T. Giordano to serve as Chief Executive Officer and a Director of the Company, effective July 14, 2021. From July 6, 2021 through July 14, 2021, Mr. Giordano
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the year ended December 31, 2020 and provided a business update. “Now that the merger with PH Precision Medicine is complete, we have clinical development programs in group one and group two Pulmonary Hypertension patients,” stated Anthony DiTonno, Chief Executive Officer of Tenax, “which represent more than 70% of the overall market.” “Having acquired the oral formulation rights of Levosim
Gainers Qualigen Therapeutics (NASDAQ:QLGN) shares moved upwards by 42.5% to $0.25 during Thursday's regular session. The company's market cap stands at $1.5 million. The company's, Q1 earnings came out 2 days ago. Sharps Technology (NASDAQ:STSS) stock rose 33.56% to $0.31. The market value of their outstanding shares is at $6.1 million. Autonomix Medical (NASDAQ:AMIX) shares increased by 21.43% to $0.78. The market value of their outstanding shares is at $14.6 million. Akso Health Group (NASDAQ:AHG) stock rose 11.68% to $1.29. The company's market cap stands at $189.2 million. Conduit Pharmaceuticals (NASDAQ:CDT) stock rose 10.74% to $0.71. The company's market cap stands at $52.3 mill
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(3.12) per share which missed the analyst consensus estimate of $(2.40) by 30 percent. This is a 74 percent increase over losses of $(12.00) per share from the same period last year.
Shares of Alcoa Corporation (NYSE:AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter. The company reported quarterly losses of 81 cents per share, according to data from Benzinga Pro. Alcoa still sees full-year alumina production of between 9.8 million and 10 million metric tons and full-year alumina shipments between 12.7 million and 12.9 million metric tons. Alcoa shares jumped 3% to $36.60 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) shares gained 155.6% to $1.24 in pre-market trading after gaining around 8% on Wednesday. Mic
Tenax Therapeutics (NASDAQ:TENX) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Tenax Therapeutics missed estimated earnings by -45.0%, reporting an EPS of $-11.84 versus an estimate of $-8.14. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $1.6 which was followed by a 19.0% drop in the share price the next day. To track all earnings releases for Tenax Therapeutics visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(11.84) per share which missed the analyst consensus estimate of $(8.14) by 45.45 percent. This is a 83.74 percent increase over losses of $(72.80) per share from the same period last year.
Shares of Fangdd Network Group Ltd. (NASDAQ:DUO) rose sharply in today’s pre-market trading after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector. Fangdd Network Group shares jumped 78.3% to $1.08 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Kidpik Corp. (NASDAQ:PIK) gained 311% to $11.10 in pre-market trading. Kidpik recently announced a 1-for 5 reverse stock split. Auddia Inc. (NASDAQ:AUUD) shares rose 50.1% to $4.64 in pre-market trading after falling over 8% on Friday. Mesoblast Limited (NASDAQ:MESO) rose 28.4% to $2.76 in pre-market trading after the company said that the F
Roth MKM analyst Jonathan Aschoff reiterates Tenax Therapeutics (NASDAQ:TENX) with a Buy and maintains $30 price target.
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
3 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)